FIELD: medicine.
SUBSTANCE: present invention refers to immunology. Disclosed are an antibody and antibody fragment, capable of binding to phosphorylcholine and / or phosphorylcholine conjugate. Also disclosed is a pharmaceutical composition, a nucleic acid encoding an antibody or a fragment thereof, an expression vector, a host cell, and a method for producing an antibody or antibody fragment. Also described is a method for preparing an antibody variant, capable of binding to phosphorylene and / or phosphorylcholine conjugate, or a fragment of such an antibody.
EFFECT: present invention can find further application in the therapy of various conditions, in particular cardiovascular diseases and Alzheimer's disease.
16 cl, 7 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND USE THEREOF | 2016 |
|
RU2705540C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| ANTIBODIES AGAINST HEPATITIS B VIRUS AND THEIR USE | 2020 |
|
RU2803082C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| ANTIBODIES AND CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO CD19 | 2015 |
|
RU2741105C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
| CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
| UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
